(Q35932749)

11 August 2017

Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease (English)

1 reference

11 August 2017

0 references

1 reference

Michael Jeffrey Aminoff

9

object named as

Michael J Aminoff

1 reference

11 August 2017

Gabriele Mittermeyer

1

1 reference

11 August 2017

Chadwick W Christine

2

1 reference

11 August 2017

Kathryn H Rosenbluth

3

1 reference

11 August 2017

Suzanne L Baker

4

1 reference

11 August 2017

Philip Starr

5

1 reference

11 August 2017

Paul Larson

6

1 reference

11 August 2017

Paul L Kaplan

7

1 reference

11 August 2017

John Forsayeth

8

1 reference

11 August 2017

Krystof S Bankiewicz

10

1 reference

11 August 2017

10 April 2012

1 reference

11 August 2017

1 reference

11 August 2017

23

1 reference

11 August 2017

4

1 reference

11 August 2017

377-381

1 reference

Novel platform for MRI-guided convection-enhanced delivery of therapeutics: preclinical validation in nonhuman primate brain

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4530392

Subregional 6-[18F]fluoro-ʟ-m-tyrosine uptake in the striatum in Parkinson's disease.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4530392

Gene therapy for Parkinson's disease: where are we now and where are we going?

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4530392

Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4530392

Qualitative imaging of adeno-associated virus serotype 2-human aromatic L-amino acid decarboxylase gene therapy in a phase I study for the treatment of Parkinson disease.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4530392

Safety and tolerability of putaminal AADC gene therapy for Parkinson disease

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4530392

Striatal volume differences between non-human and human primates

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4530392

Biodistribution of adeno-associated virus type-2 in nonhuman primates after convection-enhanced delivery to brain

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4530392

Results from a phase I safety trial of hAADC gene therapy for Parkinson disease

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4530392

Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4530392

A dose-ranging study of AAV-hAADC therapy in Parkinsonian monkeys

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4530392

The placebo effect in Parkinson's disease

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4530392

Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4530392

Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4530392

Quantification of mRNA of tyrosine hydroxylase and aromatic L-amino acid decarboxylase in the substantia nigra in Parkinson's disease and schizophrenia

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4530392

Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4530392

PET studies of functional compensation in a primate model of Parkinson's disease

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4530392

Gait analysis in patients with Parkinson's disease and motor fluctuations: influence of levodopa and comparison with other measures of motor function

24 September 2018

1 reference

12 December 2020

Intrastriatal transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson's disease: a double-blind, randomised, controlled trial

1 reference

12 December 2020

Rating impairment and disability in Parkinson's disease: evaluation of the Unified Parkinson's Disease Rating Scale

1 reference

12 December 2020

T2 imaging in monitoring of intraparenchymal real-time convection-enhanced delivery

1 reference

12 December 2020

Identifiers

DOI

10.1089/HUM.2011.220

1 reference

11 August 2017

1 reference

11 August 2017

PubMed publication ID

22424171

1 reference